Targeted drugs for non-Hodgkin’s lymphoma, including rituximab injection, CD19 molecular recombinant protein and other drug therapy.
1. Rituximab injection: it can target and kill CD20-positive B-cell non-Hodgkin’s lymphoma cells for CD20-positive B-cell monoclonal antibody for targeted drug therapy.
2. CD19 molecular recombinant protein: CD19 is a type 1 transmembrane glycoprotein, which generally plays an important role in the growth and development of B cells, and can participate in the transduction of B cell signals and improve the sensitivity of B cells to antigens, and can be used for the treatment of a variety of malignant tumors of the B lymphatic system.
The treatment of the disease must be based on the patient’s own specific circumstances, under the guidance of the doctor standardized use of drugs, do not take drugs on their own.